An open-label study of leukocyte counts in the cerebrospinal fluid and
An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast
What was tested
Treatment tested
- Firategrast
Integrin alpha-4/beta-1 antagonist|Integrin alpha-4/beta-7 antagonist
What it measured
Main measures
The primary outcome measures are the number and change in number of total leukocytes, total lymphocytes and lymphocyte subsets (CD4+ and CD8+ T-lymphocytes, CD19+ B-lymphocytes, CD34+ early hematopoietic progenitor cells) and the CD4:CD8 ratio in the CSF and/or blood. The time points of interest for all of the above endpoints are Baseline, Treatment Week 4 (CD34+ early hematopoietic progenitor ce
Blood or spinal fluid markersImmune response
Loading reviews and guidelines…
Related trials
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Recruiting
Still running
- A Study Utilising Data From European Union (EU) National Multiple Scle
Running, not recruiting
Still running
- A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated M
Stopped early
Stopped
- A Study to Investigate the Radiological Onset of Action After Treatmen
Phase 4 · Stopped early
Stopped
- The 'Wearing Off' Effect of DMT
Completed
No results found
- A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacody
Phase 3 · Stopped early
Stopped: not working
History
- In scope changed from true to false
Started
Feb 2007